fda warning letters compounded semaglutide tirzepatide 2025 Last month, the issued 25 to telehealth companies over what it called false or misleading claims about GLP-1 medications fda compounding semaglutide warning letters

If youre on Zepbound and not losing weight, do not lose hope

as of May 2026 is clinical trial enrollment FDA-approved alternatives exist (semaglutide, tirzepatide) with established compounding and dosing pathways and substantial clinical data Self-sourcing research peptides for human use is not safe and carries identity, purity, and contamination risks If you are a clinician: Patient questions about retatrutide source verification are increasing

One ex-vivo / in-vitro study, no clinical trial

The pivotal SURPASS clinical trial program evaluated tirzepatide in various combinations, including with metformin

Am J Med Genet A

The widespread prevalence of obesity necessitates production strategies that can meet the growing demand for anti-obesity medications without increasing the carbon footprint of these processes